GCG and Other metabolic disease: Moreover, the deletion of MGAT2 increases the level of gut incretin glucagon-like peptide-1 (GLP-1), which has many beneficial effects in treating metabolic disorders including stimulating insulin secretion, reducing glucagon, slowing gastric emptying, and inducing satiety [45].